Clinical trial DESTINY- Breast12
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12)
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3/4 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2020-005048-46 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04739761 |
Last update |